MARKET

RGLS

RGLS

Regulus Therapeu
NASDAQ
1.750
0.000
0.00%
After Hours: 1.860 +0.11 +6.29% 18:39 04/01 EDT
OPEN
1.710
PREV CLOSE
1.750
HIGH
2.050
LOW
1.670
VOLUME
2.58M
TURNOVER
--
52 WEEK HIGH
2.910
52 WEEK LOW
0.8301
MARKET CAP
115.93M
P/E (TTM)
-2.1271
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RGLS last week (0324-0328)?
Weekly Report · 1d ago
Promising Phase 1b Results and Favorable Safety Profile Position Regulus’s Farabursen as a Strong Investment in ADPKD Treatment
TipRanks · 1d ago
Promising Phase 1b Results and Future Prospects Drive Buy Rating for Regulus’s Farabursen
TipRanks · 4d ago
RNA Biotechs: Current State And Outlook
Seeking Alpha · 4d ago
Oppenheimer Reaffirms Their Buy Rating on Regulus (RGLS)
TipRanks · 4d ago
REGULUS THERAPEUTICS INC <RGLS.O>: WELLS FARGO RAISES TO OVERWEIGHT FROM EQUAL WEIGHT; RAISES TARGET PRICE TO $6 FROM $3
Reuters · 4d ago
U.S. RESEARCH ROUNDUP-Applied Materials, KLA, Oxford Industries
Reuters · 4d ago
Regulus Therapeutics Raised to Overweight From Equal-Weight by Wells Fargo
Dow Jones · 5d ago
More
About RGLS
More
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.
Recently
Symbol
Price
%Change

Webull offers Regulus Therapeutics Inc stock information, including NASDAQ: RGLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RGLS stock methods without spending real money on the virtual paper trading platform.